Author Correction: Programmable RNA targeting with the single-protein CRISPR effector Cas7-11

Ahsen Özcan, Rohan N. Krajeski, Eleonora Ioannidi, Brennan Lee, Apolonia Gardner, Kira S. Makarova, Eugene V. Koonin, Omar O. Abudayyeh, Jonathan S. GootenbergNature 2022 · DOI · OpenAlex

Introduction

In the field of CRISPR technology, molecular precision is the cornerstone of reproducibility and further innovation. This article outlines the formal author correction published in Nature regarding the characterization of Cas7-11, a novel Type III CRISPR effector. While the fundamental discovery of Cas7-11 as a single-protein RNA-targeting tool remains robust, this correction provides essential refinements to the molecular mapping, sequence accuracy, and data presentation of the original 2021 study.

The Significance of Cas7-11

The discovery of Cas7-11 represented a major milestone in genome engineering. Traditional Type III CRISPR systems typically function as large, multi-protein complexes, which complicates their delivery into target cells for therapeutic use. Cas7-11 is unique because it integrates the functional domains of these complexes into a single, massive polypeptide. This architecture offers the programmability of Type III systems—known for their high specificity and lack of "collateral" RNA cleavage—with the delivery advantages of single-protein effectors like Cas9 or Cas13.

Refinements in Molecular Mapping

The correction addresses several technical discrepancies in the initial publication that are critical for structural biology and protein engineering. In high-precision molecular biology, minor labeling errors can lead to significant hurdles for labs attempting to replicate or build upon existing work.

Sequence and Residue Accuracy

High-resolution molecular biology requires exact sequence data. The correction identifies a missing Uracil (U) in the guide-target interaction sequence in Figure 1c. In CRISPR systems, the precise alignment of the guide RNA with the target transcript determines binding affinity and cleavage efficiency; thus, every base pair in the diagram is critical for researchers designing new guides.

Furthermore, the numbering of a specific amino acid residue within the "Cas7 (domain 2)" region was corrected from 2426 to 2429. For structural biologists attempting to model the protein-RNA interface or perform site-directed mutagenesis to enhance the protein's function, this three-residue shift is vital for accurate structural interpretation and biochemical assay design.

Cleavage Site Calibration

The exact location where Cas7-11 "cuts" its target RNA is a defining characteristic of its enzymatic activity. The correction notes that the cleavage site depicted in Extended Data Figure 2d was originally presented one position higher than the experimental data supported. Correcting this "cut" site ensures that future guide designs can be optimized for maximum knockdown efficiency based on the actual biochemical behavior of the enzyme.

Data Integrity and Comparative Analysis

The original study compared the performance of Cas7-11 against established RNA-targeting tools, including LwsCas13a and PspCas13b. The correction restores missing data points in the "non-targeting control" columns for these comparators in Figure 3b. By including the full spread of experimental replicates and ensuring statistical error bars are fully supported, the correction reinforces the transparency and robustness of the comparative performance data. These updates ensure that the statistical significance of Cas7-11’s performance is accurately represented against its predecessors.

Conclusion

This author correction serves as a vital update to the technical record of the Cas7-11 system. While the core conclusion—that Cas7-11 is a programmable, single-protein RNA-targeting effector—is unchanged, the adjustments to residue numbering, sequence accuracy, and cleavage site mapping provide the scientific community with the precision necessary for further development. As researchers work to optimize these large proteins for viral delivery (such as AAV vectors), these corrected structural details will be instrumental in guiding protein engineering and therapeutic applications.

Summary updated

BibTeX
@inproceedings{ozcan2022author,
  author = {Ahsen Özcan and Rohan N. Krajeski and Eleonora Ioannidi and Brennan Lee and Apolonia Gardner and Kira S. Makarova and Eugene V. Koonin and Omar O. Abudayyeh and Jonathan S. Gootenberg and Omar Abudayyeh},
  title = {{Author Correction: Programmable RNA targeting with the single-protein CRISPR effector Cas7-11}},
  booktitle = {Nature},
  year = {2022},
  doi = {10.1038/s41586-022-05003-6},
}
Figure